Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Ebenezer Daniel(University of Pennsylvania), Maureen G. Maguire(University of Pennsylvania), Stephanie A. Hagstrom(Cleveland Clinic), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Juan E. Grunwald(University of Pennsylvania), Cynthia A. Toth(Duke University), Glenn J. Jaffe(The University of Texas Health Science Center at San Antonio), Jiayan Huang(University of Pennsylvania), Daniel Martín(Cleveland Eye Clinic), Stuart L. Fine(University of Colorado Denver), Katrina Winter(Duke University)
Cited by 325
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
|Ophthalmology|2016|702
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646